Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Prostatic Neoplasms 163Breast Neoplasms 123Lung Neoplasms 101Carcinoma, Non-Small-Cell Lung 83Glioblastoma 77Brain Neoplasms 74Neoplasm Metastasis 68Glioma 68Pancreatic Neoplasms 50Neoplasms 45Carcinoma, Renal Cell 45Multiple Myeloma 44Colorectal Neoplasms 43Squamous Cell Carcinoma of Head and Neck 39Lymphoma, Large B-Cell, Diffuse 39Carcinoma, Hepatocellular 36Ovarian Neoplasms 34Melanoma 34Lymphoma 34Urinary Bladder Neoplasms 33Astrocytoma 30Sarcoma 26Rectal Neoplasms 26Uterine Cervical Neoplasms 24Oropharyngeal Neoplasms 24Lymphoma, Follicular 24Central Nervous System Neoplasms 24Lymphoma, Non-Hodgkin 23Triple Negative Breast Neoplasms 22Gliosarcoma 22

Interventions

Nivolumab 20Ipilimumab 10Surveys and Questionnaires 7Paclitaxel 7linrodostat 6Standard of Care 6Sirolimus 5Gemcitabine 5Bevacizumab 5temsirolimus 4relatlimab 4Pemetrexed 4Interviews as Topic 4Docetaxel 4Carboplatin 4ARRY-334543 4Vorinostat 3Erlotinib Hydrochloride 3Dasatinib 3Cetuximab 3regorafenib 2olaparib 2apatinib 2anlotinib 2abemaciclib 2Trastuzumab 2Sunitinib 2Sorafenib 2Olanzapine 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Cancer × Magnetic Resonance Spectroscopy × Clear all
NCT01143779 2022-01-04

FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled

Advanced Cancer

NCT00610493 2017-12-08

Bevacizumab and Temsirolimus in Patients With Advanced Malignancy

M.D. Anderson Cancer Center

Phase 1 Completed
193 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡